drugset
Drugs / XH-S003
last change Apr 2026 re-read 3 minutes ago

XH-S003

Developed for
paroxysmal nocturnal hemoglobinuria · IgA glomerulonephritis
Investigated by
S-INFINITY Pharmaceuticals Co., Ltd

Trials 5

today NCT07657052 · not/applicable NCT06978699 · Ph 2 NCT07634744 · Ph 2 NCT05946876 · Ph 1 NCT06272747 · Ph 1
202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT05946876 Aug 2023 → Jul 2024 — S-INFINITY Pharmaceuticals Co., Ltd Completed No outcome recorded
Phase 1 NCT06272747 Jul 2023 → Jul 2024 — S-INFINITY Pharmaceuticals Co., Ltd Completed No outcome recorded
Phase 22 trials
Phase 2 NCT06978699 Apr → Aug 2025 overdue paroxysmal nocturnal hemoglobinuria S-INFINITY Pharmaceuticals Co., Ltd Recruiting No outcome recorded
Phase 2 NCT07634744 Dec 2024 → Apr 2026 IgA glomerulonephritis S-INFINITY Pharmaceuticals Co., Ltd Completed No outcome recorded
Phase not applicable1 trial
— NCT07657052 Aug 2025 → Sep 2029 expected paroxysmal nocturnal hemoglobinuria S-INFINITY Pharmaceuticals Co., Ltd Enrolling by invitation No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2025-03-13 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Regulatory Fosun Pharma’s Independently Developed Innovative Drug XH-S003 Capsule for PNH Indication Approved for Clinical Trials fosunpharma.com ↗
The approval of Phase II clinical trials for XH-S003 marks another milestone in Fosun Pharma’s continuous innovation in rare diseases.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as XH-S003 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07657052 ↗
4

NCT07634744 ↗

NCT05946876 ↗

NCT06272747 ↗

NCT06978699 ↗
Route Oral “Route of Administration: Oral” NCT05946876 ↗